Takeaways: Silo Pharma’s CIPO Notice of Allowance for SPC‑15 strengthens its IP moat around a prophylactic, intranasal 5‑HT4 agonist approach for PTSD and stress‑induced disorders, complementing a rec...
Browsing Tag: intranasal therapeutics
Takeaways: Silo Pharma’s CIPO Notice of Allowance for SPC‑15 strengthens its IP moat around a prophylactic, intranasal 5‑HT4 agonist approach for PTSD and stress‑induced disorders, complementing a rec...